[TLOG] TetraLogic Pharmaceuticals Corporation
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For TLOG
TLOG is in the medium-term down -66% in 1 year. In the long-term down -72% below S&P in 2 years and down -100% below S&P in 7 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical company in the United States. The company focuses on discovering and developing novel small molecule therapeutics that mimic novel second mitochondrial activator of caspases to cause or enable abnormal cells, which are resistant to the body?s immune system to self-destruct. Its clinical-stage product candidate, Birinapant, is in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The company?s clinical and pre-clinical programs comprise an ongoing Phase I/II clinical trial of birinapant as a single agent in various blood cancers; a Phase I/II completed clinical trial of birinapant administered with irinotecan in colorectal cancer; and a Phase I/II clinical trial of birinapant administered with conatumumab in ovarian cancer, as well as an intention to start Phase I clinical trial in hepatitis B virus. It has collaboration with Amgen, Inc. for exploring the combination of bir
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -39.24% | ROE | -176.91% | ROI | -50.03% | |
| Current Ratio | 6.96 | Quick Ratio | Long Term Debt/Equity | 0.72 | Debt Ratio | 0.28 | |
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | -800 K | Cash From Investing Activities | 11.91 M | Cash From Operating Activities | -7.24 M | Gross Profit | |
| Net Profit | -12.68 M | Operating Profit | -10.63 M | Total Assets | 110.35 M | Total Current Assets | 48.1 M |
| Total Current Liabilities | 6.91 M | Total Debt | 27.56 M | Total Liabilities | 85.88 M | Total Revenue |
Technical Data
| High 52 week | 0.04 | Low 52 week | 0.01 | Last close | 0.01 | Last change | -13.95% |
| RSI | 57.56 | Average true range | Beta | 0.44 | Volume | 104.24 K | |
| Simple moving average 20 days | 14.37% | Simple moving average 50 days | 27.79% | Simple moving average 200 days | -38.03% |
Performance Data
| Performance Week | 30.59% | Performance Month | 11% | Performance Quart | -17.16% | Performance Half | -41.58% |
| Performance Year | -55.6% | Performance Year-to-date | 58.57% | Volatility daily | 27.28% | Volatility weekly | 61% |
| Volatility monthly | 125.02% | Volatility yearly | 433.09% | Relative Volume | 84.1% | Average Volume | 13.38 K |
| New High | New Low |
News
2016-12-30 08:25:14 | TetraLogic completes $12M asset sale to Swedish drug developer
2016-12-30 07:45:06 | TetraLogic complete $12M asset sale to Swedish drug developer
2016-12-29 10:30:00 | TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
2016-11-22 08:27:07 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to
2016-11-14 17:07:17 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements
2016-11-08 13:04:13 | TETRALOGIC PHARMACEUTICALS CORP Financials
2016-11-04 12:20:12 | $12M deal: Malvern biopharm firm sells assets to Swedish drug developer
2016-11-03 17:29:22 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with
2016-11-02 18:07:15 | TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock
2016-11-02 16:51:00 | Medivir Strengthens Its Clinical Pipeline by Entering into Agreement to Acquire a Portfolio of Clinical Stage Oncology Programs
2016-11-02 16:45:19 | Medivir strengthens its clinical pipeline by entering into agreement to acquire a portfolio of clinical stage oncology programs
2016-11-02 16:30:00 | TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock
2016-10-19 16:07:21 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul
2016-09-06 16:06:14 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul
2016-09-01 16:03:40 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul
2016-08-11 13:24:34 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
2016-07-22 16:19:59 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers
2016-07-20 16:21:25 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul
2016-06-15 16:06:50 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
2016-05-04 13:32:39 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
2016-04-26 08:26:00 | 4 Trending Small Cap Stocks That You Need To Watch Today
2016-04-25 12:44:00 | Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
2016-04-15 12:09:00 | Top Penny Stocks: Four Small Cap Stocks You Should Be Watching On April 15th
2016-04-07 16:07:21 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers
2016-03-16 15:31:04 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report
2016-02-26 07:01:48 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul
2016-02-03 13:49:00 | These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
2016-02-03 12:37:22 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers
2016-01-13 09:45:00 | Insider Alert: Here's Why These Small Caps Could Be Ready To Bounce…
2016-01-07 11:12:02 | TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs
2016-01-07 08:41:15 | Here's Why Tetralogic Pharmaceuticals Is Down 70%
2015-12-31 10:02:00 | LifeSci Capital Initiates Coverage of TetraLogic Pharmaceuticals Corporation
2015-12-31 08:30:50 | Roth Capital's New Buy Rating On TetraLogic: 'SMAC'ing Cancer Around'
2015-11-06 09:52:09 | Odey Asset Management and Clinton Group Discarding Two Low-Priced Stocks, While Whitebox Advisors Goes Long This Biotech
2015-10-07 08:14:00 | Pharmaceutical Sector Due Diligence Report - Searching for Opportunities Among the Bruised Small Cap Market